Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3757-3761

  Rhodes, Nathaniel J ^a,b   Richardson, Chad L ^b   Heraty, Ryan ^a   Liu, Jiajun ^a   Malczynski, Michael ^b   Qi, Chao ^b   Scheetz, Marc H ^a,b  

^a MIDWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE CTX M; BETA LACTAMASE TEM; CEFEPIME; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BLOOD SAMPLING; BODY FLUID; CLASSIFICATION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GENOTYPE; GOLD STANDARD; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VITEK 2 CLASSIFICATION; BACTERIAL GENE; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; REPRODUCIBILITY; STANDARDS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENES, BACTERIAL; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS;

EID: 84903209776     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00041-14     Document Type: Article

References (25)

1. Cantón R, Perez-Vazquez M, Oliver A, Coque TM, Loza E, Ponz F, Baquero F. 2001. Validation of the VITEK2 and the Advance Expert System with a collection of Enterobacteriaceae harboring extended spectrum or inhibitor resistant beta-lactamases. Diagn. Microbiol. Infect. Dis. 41:65-70. http://dx.doi.org/10.1016/S0732-8893(01)00286-3. (Pubitemid 33001461)
2. Esquisabel ABC, Rodriguez MC, Campo-Sosa AO, Rodriguez C, Martinez-Martinez L. 2011. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime. Clin. Microbiol. Infect. 17:1817-1822. http://dx.doi.org/10.1111/j.1469-0691.2011. 03530.x.
3. Jang W, Park YJ, Park KG, Yu J. 2013. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime. J. Antimicrob. Chemother. 68:2282-2285. http://dx.doi.org/10.1093/jac/dkt172.
4. Jones RN, Biedenbach DJ, Marshall SA, Pfaller MA, Doern GV. 1998. Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime. Diagn. Microbiol. Infect. Dis. 32:107-110. http://dx.doi.org/10.1016/S0732-8893(98)00051-0. (Pubitemid 28526451)
5. Juretschko S, LaBombardi VJ, Lerner SA, Schreckenberger PC, Pseudomonas AST Study Group. 2007. Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2). J. Clin. Microbiol. 45:1339-1342. http://dx.doi.org/10.1128/JCM.01716-06. (Pubitemid 46626512)
6. Munoz-Davila MJ, Yague G, Albert M, Garcia-Lucas T. 2012. Comparative evaluation of Vitek 2 identification and susceptibility testing of Gram-negative rods directly and isolated from BacT/ALERT-positive blood culture bottles. Eur. J. Clin. Microbiol. Infect. Dis. 31:663-669. http://dx.doi.org/10.1007/s10096- 011-1356-1.
7. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing. CLSI M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN, Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute. 2013. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa : I. Cephalosporins and aztreonam. Clin. Infect. Dis. 56:1301-1309. http://dx.doi.org/10.1093/cid/cit017.
9. Pottumarthy S, Deshpande LM, Sader HS, Jones RN. 2005. Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms. Diagn. Microbiol. Infect. Dis. 52:95-99. http://dx.doi.org/10.1016/j.diagmicrobio.2004.12.004. (Pubitemid 40826934)
10. Jones RN, Craig WA, Ambrose PG, Dudley MN, Pottumarthy S. 2005. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases. Diagn. Microbiol. Infect. Dis. 52:235-246. http://dx.doi.org/10.1016/j.diagmicrobio.2005.02.006. (Pubitemid 41133550)
11. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing. CLSI M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Qi C, Pilla V, Yu JH, Reed K. 2010. Changing prevalence of Escherichia coli with CTX-M-type extended-spectrum beta-lactamases in outpatient urinary E. coli between 2003 and 2008. Diagn. Microbiol. Infect. Dis. 67: 87-91. http://dx.doi.org/10.1016/j.diagmicrobio.2009.12.011.
13. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing. CLSI M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing. CLSI M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing. CLSI M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. CLSI M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. CLSI M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
18. National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing. NCCLS M100-S14. National Committee for Clinical Laboratory Standards, Wayne, PA.
19. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing. NCCLS M100-S13. National Committee for Clinical Laboratory Standards, Wayne, PA.
20. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA. 2007. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:1621-1626. http://dx.doi.org/10. 1128/AAC.01099-06. (Pubitemid 46744136)
22. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing. CLSI M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
23. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. 2009. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems. Department of Health and Human Services, Washington, DC.
24. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters. CLSI M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
25. Esterly JS, Qi C, Malczynski M, Scheetz MH. 2010. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status. Pharmacotherapy 30:354-360. http://dx.doi.org/10.1592/phco.30.4.354.